Helmholtz Gemeinschaft


Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

Item Type:Article
Title:Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
Creators Name:Davies, F.E. and Raje, N. and Hideshima, T. and Lentzsch, S. and Young, G. and Tai, Y.T. and Lin, B. and Podar, K. and Gupta, D. and Chauhan, D. and Treon, S.P. and Richardson, P.G. and Schlossman, R.L. and Morgan, G.J. and Muller, G.W. and Stirling, D.I. and Anderson, K.C.
Abstract:The antiangiogenic activity of thalidomide (Thal), coupled with an increase in bone marrow angiogenesis in multiple myeloma (MM), provided the rationale for the use of Thal in MM. Previously, the direct anti-MM activity of Thal and its analogues (immunomodulatory drugs, IMiDs) on MM cells was demonstrated, suggesting multiple mechanisms of action. In this study, the potential immunomodulatory effects of Thal/IMiDs in MM were examined. It was demonstrated that Thal/IMiDs do not induce T-cell proliferation alone but act as costimulators to trigger proliferation of anti-CD3-stimulated T cells from patients with MM, accompanied by an increase in interferon-gamma and IL-2 secretion. However, an increase in autologous T-cell killing of patient MM cells could not be demonstrated. A role for natural killer (NK)- and LAK-cell-mediated killing is suggested because IL-2-primed peripheral blood mononuclear cells (PBMCs) treated with Thal/IMiDs demonstrated significantly increased lysis of MM cell lines. Cold target inhibition assays suggested NK- rather than LAK-cell-mediated killing. Furthermore, this killing was not major histocompatibility complex-class restricted, and the depletion of CD56(+) cells blocked the drug-induced MM cell lysis. It was significant that increased killing of patient MM cells by autologous PBMCs treated with Thal/IMiDs was also observed. Although the in vivo relevance of NK-cell-mediated MM cell killing is unknown, phenotypic analysis performed in MM patients receiving Thal therapy demonstrated an increase in CD3(-)CD56(+) cells in patients responding to therapy. Thus in vitro and in vivo data support the hypothesis that Thal may mediate its anti-MM effect, at least in part, by modulating NK cell number and function.
Keywords:Immunologic Adjuvants, Case-Control Studies, Immunologic Cytotoxicity, Immunophenotyping, Natural Killer Cells, Lymphocyte Count, Multiple Myeloma, T-Lymphocytes, Thalidomide, Cultured Tumor Cells
Publisher:American Society of Hematology
Page Range:210-216
Date:1 July 2001
Official Publication:https://doi.org/10.1182/blood.V98.1.210
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library